# US 2019/0375826 A1 · Anti-dengue virus antibodies and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375826 A1
- Document ID: US20190375826A1
- Status: Published application
- Kind: A1
- Application number: 16/006,000
- Filed: 2018-06-12
- Published: 2019-12-12
- Earliest claimed: 2018-06-12
- Assignees: National Defense Medical Center
- Applicants: National Defense Medical Center
- Inventors: Szu-Chia LAI; Yu-Yine HUANG; Chang-Chi LIN; Jiunn-Jye WEY; Meng-Hung TSAI
- Web page: https://patentgrep.com/patent/US20190375826A1

## CPC

- C07K 16/116: Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- G01N 33/56983: {Viruses}
- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- C07K 2317/31: multispecific
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- G01N 2333/185: Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to anti-virus dengue virus antibodies and applications thereof. Specifically, the anti-virus dengue virus antibodies of the present invention are serotype specific and useful for specific detection and differentiation of various dengue virus serotypes in a biological sample. The present invention also provide methods and kits for detecting dengue virus and methods and compositions for use in diagnosis and treatment of dengue virus disease using the anti-virus dengue virus antibodies as described herein.

## Claims

### Claim 1

An isolated antibody or antigen-binding fragment thereof specific for dengue virus, wherein the isolated antibody is selected from the group consisting of:
(i) a first antibody specific for dengue virus serotype 1 (DENV1) comprising
(a) a heavy chain variable region (VH) which comprises a heavy chain complementary determining region (HC CDR1) of SEQ ID NO: 2, a heavy chain complementary determining region 2 (HC CDR2) of SEQ ID NO: 4, and a heavy chain complementary determining region 3 (HC CDR3) of SEQ ID NO: 6; and
(b) a light chain variable region (VL) which comprises a light chain complementary determining region 1 (LC CDR1) of SEQ ID NO: 9, a light chain complementary determining region (LC CDR2) of SEQ ID NO: 11, and a light chain complementary determining region 3 (LC CDR3) of SEQ ID NO: 13;
(ii) a second antibody specific for dengue virus serotype 2 (DENV2) comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO: 16, a HC CDR2 of SEQ ID NO: 18, and a HC CDR3 of SEQ ID NO: 20; and
(b) a VL which comprises a LC CDR1 of SEQ ID NO: 23, a LC CDR2 of SEQ ID NO: 25, and a LC CDR3 of SEQ ID NO: 27;
(iii) a third antibody specific for dengue virus serotype 3 (DENV3) comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO: 30, a HC CDR2 of SEQ ID NO: 32, and a HC CDR3 of SEQ ID NO: 34; and
(b) a VL which comprises a LC CDR1 of SEQ ID NO: 37, a LC CDR2 of SEQ ID NO: 39, and a LC CDR3 of SEQ ID NO: 41;
(iv) a fourth antibody specific for dengue virus serotype 4 (DENV4) comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO: 44, a HC CDR2 of SEQ ID NO: 46, and a HC CDR3 of SEQ ID NO: 48; and
(b) a VL which comprises a LC CDR1 of SEQ ID NO: 51, a LC CDR2 of SEQ ID NO: 53, and a LC CDR3 of SEQ ID NO: 55; and
(v) a fifth antibody cross-reactive to DENV1, DENV2, DENV3 and DENV4 comprising
(a) a VH which comprises a HC CDR1 of SEQ ID NO: 58, a HC CDR2 of SEQ ID NO: 60, and a HC CDR3 of SEQ ID NO: 62; and
(b) a VL which comprises a LC CDR1 of SEQ ID NO: 65, a LC CDR2 of SEQ ID NO: 67, and a LC CDR3 of SEQ ID NO: 69; and
(vi) any combination of (i) to (v).

### Claim 2 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein
(i) the first antibody comprises a VH that comprises SEQ ID NO: 71 and a VL comprising SEQ ID NO: 72;
(ii) the second antibody comprises a VH comprising SEQ ID NO: 73 and a VL comprising SEQ ID NO: 74;
(iii) the third antibody comprises a VH comprising SEQ ID NO: 75 and a VL comprising SEQ ID NO: 76;
(iv) the fourth antibody comprises a VH comprising SEQ ID NO: 77 and a VL comprising SEQ ID NO: 78; and/or
(v) the fifth antibody comprises a VH comprising SEQ ID NO: 79 and a VL comprising SEQ ID NO: 80.

### Claim 3 (depends on 1)

The isolated antibody or antigen-binding fragment of claim 1, wherein the antigen-binding fragment is selected from the group consisting of scFv, (scFv)2, Fab, Fab′, and F(ab′)2 of the isolated antibody specific for dengue virus.

### Claim 4 (depends on 1)

A composition comprising the isolated antibody or antigen-binding fragment thereof of claim 1.

### Claim 5 (depends on 4)

The composition of claim 4, which is a pharmaceutical or diagnostic composition for use in treatment or diagnosis of dengue virus disease.

### Claim 6 (depends on 4)

The composition of claim 4, which comprises a pharmaceutically acceptable carrier.

### Claim 7

A method for detecting dengue virus in a sample suspected of containing said dengue virus, comprising contacting the sample with an isolated antibody or antigen-binding fragment thereof specific for dengue virus, and assaying binding of the antibody with said sample, wherein the isolated antibody is selected from the group consisting of:
(i) a first antibody specific for dengue virus serotype 1 (DENV1) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 2, a HC CDR2 of SEQ ID NO: 4, and a HC CDR3 of SEQ ID NO: 6; and a VL comprising a LC CDR1 of SEQ ID NO: 9, a LC CDR2 of SEQ ID NO: 11, and a LC CDR3 of SEQ ID NO: 13;
(ii) a second antibody specific for dengue virus serotype 2 (DENV2) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 16, a HC CDR2 of SEQ ID NO: 18, and a HC CDR3 of SEQ ID NO: 20; and a VL comprising a LC CDR1 of SEQ ID NO: 23, a LC CDR2 of SEQ ID NO: 25, and a LC CDR3 of SEQ ID NO: 27;
(iii) a third antibody specific for dengue virus serotype 3 (DENV3) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 30, a HC CDR2 of SEQ ID NO: 32, and a HC CDR3 of SEQ ID NO: 34; and a VL comprising a LC CDR1 of SEQ ID NO: 37, a LC CDR2 of SEQ ID NO: 39, and a LC CDR3 of SEQ ID NO: 41;
(iv) a forth antibody specific for dengue virus serotype 4 (DENV4) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 44, a HC CDR2 of SEQ ID NO: 46, and a HC CDR3 of SEQ ID NO: 48; and a VL comprising a LC CDR1 of SEQ ID NO: 51, a LC CDR2 of SEQ ID NO: 53, and a LC CDR3 of SEQ ID NO: 55; and
(v) any combination of (i) to (iv).

### Claim 8 (depends on 7)

The method of claim 7, wherein each of the first antibody, the second antibody, the third antibody and the fourth antibody, is paired with a partner antibody.

### Claim 9 (depends on 8)

The method of claim 8, wherein the partner antibody is a serotype cross-reactive antibody to dengue virus which comprises
(a) a VH which comprises a HC CDR1 of SEQ ID NO: 58, a HC CDR2 of SEQ ID NO: 60, and a HC CDR3 of SEQ ID NO: 62; and
(b) a VL which comprises a LC CDR1 of SEQ ID NO: 65, a LC CDR2 of SEQ ID NO: 67, and a LC CDR3 of SEQ ID NO: 69.

### Claim 10 (depends on 7)

The method of claim 7, wherein
(i) binding of the first antibody with the sample is an indicative of the presence of DENV1 in the sample;
(ii) binding of the second antibody to the dengue virus is an indicative of the presence of DENV2 in the sample;
(iii) binding of the third antibody to the dengue virus is an indicative of the presence of DENV3 in the sample; and/or
(iv) binding of the fourth antibody to the dengue virus is an indicative of the presence of DENV4 in the sample.

### Claim 11

A kit for detecting the presence of dengue virus in a sample, wherein the kit comprises one or more antibodies specific to dengue virus, selected from the group consisting of:
(i) a first antibody specific for dengue virus serotype 1 (DENV1) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 2, a HC CDR2 of SEQ ID NO: 4, and a HC CDR3 of SEQ ID NO: 6; and a VL comprising a LC CDR1 of SEQ ID NO: 9, a LC CDR2 of SEQ ID NO: 11, and a LC CDR3 of SEQ ID NO: 13;
(ii) a second antibody specific for dengue virus serotype 2 (DENV2) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 16, a HC CDR2 of SEQ ID NO: 18, and a HC CDR3 of SEQ ID NO: 20; and a VL comprising a LC CDR1 of SEQ ID NO: 23, a LC CDR2 of SEQ ID NO: 25, and a LC CDR3 of SEQ ID NO: 27;
(iii) a third antibody specific for dengue virus serotype 3 (DENV3) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 30, a HC CDR2 of SEQ ID NO: 32, and a HC CDR3 of SEQ ID NO: 34; and a VL comprising a LC CDR1 of SEQ ID NO: 37, a LC CDR2 of SEQ ID NO: 39, and a LC CDR3 of SEQ ID NO: 41;
(iv) a forth antibody specific for dengue virus serotype 4 (DENV4) that comprises a VH comprising a HC CDR1 of SEQ ID NO: 44, a HC CDR2 of SEQ ID NO: 46, and a HC CDR3 of SEQ ID NO: 48; and a VL comprising a LC CDR1 of SEQ ID NO: 51, a LC CDR2 of SEQ ID NO: 53, and a LC CDR3 of SEQ ID NO: 55;
(v) any combination of (i) to (iv); and
(vi) an optional partner antibody.

### Claim 12 (depends on 11)

The kit of claim 11, wherein the partner antibody is a serotype cross-reactive antibody to dengue virus which comprises
(a) a VH which comprises a HC CDR1 of SEQ ID NO: 58, a HC CDR2 of SEQ ID NO: 60, and a HC CDR3 of SEQ ID NO: 62; and
(b) a VL which comprises a LC CDR1 of SEQ ID NO: 65, a LC CDR2 of SEQ ID NO: 67, and a LC CDR3 of SEQ ID NO: 69.

### Claim 13 (depends on 11)

The kit of claim 11, wherein at least one of the serotype-specific antibodies or the partner antibody comprises a detectable label.

### Claim 14 (depends on 13)

The kit of claim 13, wherein the detectable label is selected from the group consisting of an enzymatic label, a fluorescent label, a metal label and a radio label.

### Claim 15 (depends on 13)

The kit of claim 13, wherein the detectable label is selected from the group consisting of gold nanoparticles, colored latex beads, magnetic particles, carbon nanoparticles, selenium nanoparticles.

### Claim 16 (depends on 11)

The kit of claim 11, wherein the kit is an immunoassay kit.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the immunoassay is selected from the group consisting of ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), FIA (fluorescence immunoassay), LIA (luminescence immunoassay), or ILMA immunoluminometric assay.

### Claim 18 (depends on 16)

The kit of claim 16, wherein the immunoassay is in a lateral flow assay format.

### Claim 19 (depends on 16)

The kit of claim 16, wherein the immunoassay is a sandwich assay.

### Claim 20 (depends on 1)

A nucleic acid comprising a nucleotide sequence encoding a heavy chain variable region (VH), a light chain variable region (VL) or both, wherein the VH and VL are as set forth in claim 1.

### Claim 21 (depends on 20)

A host cell comprising the nucleic acid of claim 20.
